Toll Free: 1-888-928-9744

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 469 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2016', provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
- The report reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 6 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 7 Therapeutics Development 8 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies 10 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes 15 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance 17 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies 21 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes 26 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 28 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 82 Drug Profiles 99 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Recent Pipeline Updates 293 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 440 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 446 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 448 Appendix 457
List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2016 19 Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H1 2016 20 Number of Products under Development by Companies, H1 2016 22 Number of Products under Development by Companies, H1 2016 (Contd..1) 23 Number of Products under Development by Companies, H1 2016 (Contd..2) 24 Number of Products under Development by Companies, H1 2016 (Contd..3) 25 Number of Products under Investigation by Universities/Institutes, H1 2016 27 Comparative Analysis by Late Stage Development, H1 2016 28 Comparative Analysis by Clinical Stage Development, H1 2016 29 Comparative Analysis by Early Stage Development, H1 2016 30 Comparative Analysis by Unknown Stage Development, H1 2016 31 Products under Development by Companies, H1 2016 32 Products under Development by Companies, H1 2016 (Contd..1) 33 Products under Development by Companies, H1 2016 (Contd..2) 34 Products under Development by Companies, H1 2016 (Contd..3) 35 Products under Development by Companies, H1 2016 (Contd..4) 36 Products under Investigation by Universities/Institutes, H1 2016 37 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 38 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor BioScience Corporation, H1 2016 39 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Aprea AB, H1 2016 40 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H1 2016 41 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 42 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc., H1 2016 43 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 44 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Baxalta Incorporated, H1 2016 45 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 46 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2016 47 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Biogenomics Limited, H1 2016 48 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx, Ltd., H1 2016 49 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioSight Ltd., H1 2016 50 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical, Inc., H1 2016 51 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2016 52 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corporation, H1 2016 53 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 54 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 55 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 56 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eisai Co., Ltd., H1 2016 57 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EpiZyme, Inc., H1 2016 58 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 59 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galena Biopharma, Inc., H1 2016 60 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd., H1 2016 61 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics, Inc., H1 2016 62 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by HEC Pharm Co., Ltd., H1 2016 63 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics S.A., H1 2016 64 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2016 65 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corporation, H1 2016 66 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016 67 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Johnson & Johnson, H1 2016 68 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc., H1 2016 69 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corporation, H1 2016 70 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 71 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 72 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 73 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mirna Therapeutics, Inc., H1 2016 74 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Limited, H1 2016 75 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H1 2016 76 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 77 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Oribase Pharma, H1 2016 78 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Panther Biotechnology, Inc., H1 2016 79 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc., H1 2016 80 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar, S.A., H1 2016 81 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corporation, H1 2016 82 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Polyphor Ltd., H1 2016 83 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sanofi, H1 2016 84 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Selvita S.A., H1 2016 85 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd., H1 2016 86 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics, Inc., H1 2016 87 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 88 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 89 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Targazyme, Inc., H1 2016 90 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 91 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 92 Assessment by Monotherapy Products, H1 2016 93 Assessment by Combination Products, H1 2016 94 Number of Products by Stage and Target, H1 2016 96 Number of Products by Stage and Mechanism of Action, H1 2016 102 Number of Products by Stage and Route of Administration, H1 2016 107 Number of Products by Stage and Molecule Type, H1 2016 109 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Recent Pipeline Updates, H1 2016 304 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2016 451 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..1), H1 2016 452 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..2), H1 2016 453 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..3), H1 2016 454 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..4), H1 2016 455 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects (Contd..5), H1 2016 456 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2016 457 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products (Contd..1), H1 2016 458


List of Figures
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2016 19 Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H1 2016 20 Number of Products under Development by Companies, H1 2016 21 Number of Products under Investigation by Universities/Institutes, H1 2016 26 Comparative Analysis by Late Stage Development, H1 2016 28 Comparative Analysis by Clinical Stage Development, H1 2016 29 Comparative Analysis by Early Stage Products, H1 2016 30 Assessment by Monotherapy Products, H1 2016 93 Number of Products by Top 10 Targets, H1 2016 95 Number of Products by Stage and Top 10 Targets, H1 2016 95 Number of Products by Top 10 Mechanism of Actions, H1 2016 101 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 101 Number of Products by Routes of Administration, H1 2016 106 Number of Products by Stage and Routes of Administration, H1 2016 106 Number of Products by Top 10 Molecule Types, H1 2016 108 Number of Products by Stage and Top 10 Molecule Types, H1 2016 108

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiency

Read More...

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify